Latest news with #ovarianCancer
Medscape
09-07-2025
- Health
- Medscape
Rucaparib Benefits HRD-Negative Ovarian Cancer Subgroups
Rucaparib maintenance therapy provided consistent benefits across all subgroups of patients grouped by prognostic factors of their homologous recombination deficiency-negative ovarian cancer tumors. Vanda Salutari, MD, of the Gynecology Oncology Unit at Policlinico Agostino Gemelli in Rome, Italy, presented this and other findings of a subgroup analysis of the ATHENA-MONO trial at ESMO Gynecological (ESMO Gyn) Cancers Congress 2025. Homologous recombination deficiency (HRD)-negative disease represents the largest subgroup in ovarian cancer, comprising approximately 44% of patients in the ATHENA-MONO study, Salutari noted in her presentation. These patients, characterized as BRCA wild-type with low loss of heterozygosity (< 16%), experience worse progression-free survival (PFS) and overall survival outcomes than those with BRCA mutations or HRD-positive disease. The trial revealed encouraging efficacy data for the treatment regimen in patients who are historically associated with poor prognosis, the investigator said. In the original ATHENA-MONO analysis, rucaparib imparted a 35% reduction in progression risk compared with placebo in this subgroup of HRD-negative patients, and this 'was also supported by an interim analysis of overall survival,' she explained. The ATHENA-MONO trial enrolled patients with newly diagnosed stage III-IV advanced high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who had completed frontline platinum-doublet chemotherapy and achieved complete or partial response. Patients were randomized 4:1 to receive oral rucaparib 600 mg twice daily or placebo for up to 24 months. In the HRD-negative population (189 patients receiving rucaparib, 49 receiving placebo), rucaparib demonstrated an improvement in investigator-assessed PFS. The median PFS was 12.1 months in the rucaparib group compared with 9.1 months in the placebo group (hazard ratio [HR], 0.65; 95% CI, 0.45-0.95). The subgroup analysis revealed strong benefits in specific patient populations. The most pronounced benefit was observed in patients with measurable disease (HR, 0.25; 95% CI, 0.08-0.80) and in those with elevated CA-125 levels (HR, 0.29; 95% CI, 0.10-0.84). Patients with residual disease after chemotherapy (HR, 0.38; 95% CI, 0.19-0.79) and those who underwent interval debulking surgery (HR, 0.53; 95% CI, 0.32-0.88) also derived strong benefits. Salutari concluded her presentation by describing what she saw as the clinical implications of her research. 'First-line rucaparib maintenance reduced the risk of progression in patients with advanced, HRD-negative high-grade ovarian cancer across all prognostic factors evaluated,' Salutari emphasized. 'These data suggest that rucaparib is a potential beneficial therapeutic option for all patients, including those with HRD-negative tumors.' Potential Mechanisms Driving Efficacy Jean-Emmanuel Kurtz, MD, PhD, of the University of Strasbourg, Strasbourg, France, serving as the external discussant, explained that the benefit of PARP inhibitor therapy in HRD-negative disease seen in this trial was somewhat unexpected. 'In HRD-negative cells, in theory, PARP inhibition would not drive any outcome benefit because of synthetic lethality,' Kurtz said. 'However, we know from the PRIMA study that [PARP inhibitors] provide PFS benefit in HRD-negative patients, and this was also found in ATHENA-MONO.' Kurtz explained that PARP inhibitors may work through alternative mechanisms in HRD-negative cells, including immune activation. 'PARP inhibitors do something in those cells. They induce a senescence-like phenotype and upregulate a series of cytokines and chemokines. This senescence-associated phenotype recruits immune cells to the tumor that potentially activate immune responses,' he said. Kurtz added that tumor burden appears to also be a driver of rucaparib efficacy in the HRD-negative population. 'What is interesting here is that the hazard ratio differences might be driven by patients with poor prognosis risk factors, such as FIGO, CR-125, and measurable disease,' he said. Manageable Safety Profile The safety analysis revealed no new safety signals in the HRD-negative population, with an adverse event profile consistent with that in previous rucaparib studies. The most common any-grade treatment-emergent adverse events in patients who received rucaparib were asthenia (63.5%), nausea (59.3%), and anemia (46.6%). Salutari said that grade 3 or higher treatment-emergent adverse events were manageable, with anemia (26.5%), neutropenia (14.8%), and elevated liver enzymes (13.2%) being the most common grade 3 or higher treatment-emergent adverse events in the rucaparib group. Implications and Future Directions According to Kurtz, the results of this analysis add to growing evidence that PARP inhibitors may have utility beyond their established role in HRD-positive disease. He noted the complexity of ovarian cancer biology, describing it as 'like a jigsaw puzzle with different shapes' that includes BRCA wild-type, HRD non- BRCA , genomic and somatic BRCA -mutated populations, and a 'grey zone' of testing failures and undetected mutations. He added that the ATHENA-MONO findings complement results from other maintenance trials, including PRIMA with niraparib, suggesting a potential class effect of PARP inhibitors in HRD-negative disease. 'Data from the ATHENA-MON demonstrated that rucaparib efficacy is associated with HRD, but in HRD-negative patients, tumor burden may drive the drug efficacy,' Kurtz concluded. Further research is needed to identify biomarkers that could better predict which HRD-negative patients are most likely to benefit from maintenance therapy with PARP inhibitors, he added. Salutari reported financial relationships with MSD, AbbVie, AstraZeneca, GSK, ImmunoGen, and Menarini. Kurtz reported financial relationships with AstraZeneca, Eisai, GSK, Chugai Pharma, PharmaMar, and MSD.
Yahoo
07-07-2025
- Business
- Yahoo
Corcept Therapeutics (CORT) Announces Pivotal Data from Phase 3 ROSELLA Trial
Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 2, Corcept Therapeutics Incorporated (NASDAQ:CORT) announced pivotal data from its Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the American Society of Clinical Oncology Annual Meeting. A biologist in a lab coat studying a culture of cells to find a cure for metabolic disorders. According to the release, ROSELLA met its primary endpoint of improved progression-free survival according to assessment by blinded independent central review (PFS-BICR). A 30% reduction in disease progression risk was recorded in patients who received relacorilant in addition to nab-paclitaxel chemotherapy as compared to those who received nab-paclitaxel monotherapy only. The results also showed that relacorilant plus nab-paclitaxel was well-tolerated and exhibited a comparable safety profile between treatment arms. Adding relacorilant did not cause a rise in patients' safety burden. In fact, patients who were administered relacorilant plus nab-paclitaxel experienced a lower incidence of ascites (5.3%) compared to those who received nab-paclitaxel alone (10.5%). The occurrence of abdominal paracenteses during treatment was also lower for the former patients. Corcept Therapeutics Incorporated (NASDAQ:CORT) is a biopharmaceutical company that develops and commercializes therapies that adjust the effects of cortisol, a hormone that regulates various bodily functions. The company's flagship product, Korlym, is FDA-approved for the treatment of Cushing's syndrome, a disorder characterized by excessive cortisol production. While we acknowledge the potential of CORT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
29-06-2025
- Business
- Yahoo
AbbVie's Elahere Market Expected to Skyrocket to $6B by 2034 in Ovarian Cancer Treatment
AbbVie Inc. (NYSE:ABBV) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, the 'Elahere Market Opportunities and Strategies to 2034' report was added to offering. It stated that the global market for Elahere, which is a treatment primarily for ovarian cancer, is anticipated to experience rapid growth and is projected to surge from nearly $502.56 million in 2024 to $6.07 billion by 2034 at a CAGR of 28.68% from 2029. AbbVie, through its acquisition of ImmunoGen, is currently the sole and dominant player in the Elahere market, holding a 100% market share in 2023. AbbVie completed its acquisition of ImmunoGen on February 12 in 2024, in a deal that was valued at ~$10.1 billion. The acquisition was made to support AbbVie's oncology pipeline, particularly with Elahere. A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist. Elahere is indicated for ovarian neoplasms, which constituted the largest segment by clinical indication and accounted for 85.44% or $429.38 million of the market in 2024. This segment is expected to remain the fastest-growing with a CAGR of 29.67% during the 2024-2029 period. North America was the largest regional market for Elahere in 2024, and accounted for 97.09% of the total, or $487.92 million. AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical company that researches, develops, manufactures, commercializes, and sells medicines and therapies worldwide. While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Irish Times
25-06-2025
- Health
- Irish Times
‘They saved my life': Trinity St James's Cancer Institute is recognised for care, research and education
Dubliner Niamh Walsh was working as a cook in a creche in April last year when she noticed her left leg was about 4cm wider than her right one. She had no other symptoms and when her GP referred her to the city's St James's Hospital she did not think anything was wrong. Following an ultrasound, she was told she had a mass of around 28cm in her pelvic area. Ms Walsh was diagnosed with ependymoma of the ovary – an extremely rare type of ovarian tumour. READ MORE She underwent an eight-hour open surgery, chemotherapy and, 11 weeks ago, had a preventive hysterectomy, in which her uterus was removed to reduce the chance of the cancer returning. 'I'm an only child, so this was a really big time for my parents being told out of the blue last year that their daughter has a really rare form of cancer that requires extreme operations and chemo after,' Ms Walsh (30) said. The diagnosis was a shock to her, too, she said. She is now trying to process everything she's been through over the past year. 'Still to this day, I cry about it,' she says. 'If I hadn't had that hysterectomy I could have heard it was back in the other ovary. I'm a very anxious person and the last thing I wanted was to be told the cancer was back.' On Wednesday, the Trinity St James's Cancer Institute (TSJCI) announced it has become the first cancer unit in Ireland to be accredited as a comprehensive cancer centre – a specialised institution recognised for advanced research and a broad range of cancer services. The Organisation of European Cancer Institutes (OECI) decided the Dublin base met or exceeded robust standards in cancer care, research and education. Prof Maeve Lowery, academic director of the TSJCI, said this designation would allow the hospital to bring improvements in patient-centred care. 'This carries an international weight. So it's about international benchmarking recognised across Europe and the US that shows certain standards of integration of academic activities like research, education, with clinical care. The real goal of it is to achieve more treatment options, better treatment options for patients,' she said. Prof Lowery said the hope was this designation would provide greater access for patients to novel treatments and clinical trials, an area in which Ireland had traditionally been viewed as lagging behind. 'It's the big issue within Ireland at the moment, there's a lot of disparity. The patients we treat here – we're a public hospital – and our patients are among the lowest socio-economic in the country. So it's really important that in the public system we're providing the best we can in terms of novel treatment,' she said. Minister for Health Jennifer Carroll MacNeill said the announcement marks a 'significant advancement' in cancer care for Ireland. 'Comprehensive cancer centres like TSJCI bring an additional focus on research and training which can expand the treatment options available for patients now and into the future,' she said. This is particularly true for patients such as Ms Walsh, who have rarer forms of cancer and for whom the diagnosis can feel devastating. If it were not for the kindness from the team of clinicians who treated her, Ms Walsh said she 'wouldn't have gotten through it'. 'My type of cancer, if I hadn't have had that operation when I did, it would have spread. This hospital saved my life,' she said. 'After this whole thing, I'm seeing a different side to myself. I used to be a very shy person, but now I'm trying to get out there. I'm trying to just enjoy life, because you've got to enjoy it while we can.'
Medscape
19-06-2025
- Health
- Medscape
Key Highlights in Ovarian Cancer From ASCO 2025
Novel drug combinations that improve outcomes, outstanding questions about treatment sequence, and encouraging results in chemotherapy resistant disease are among the ovarian cancer highlights presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Stephanie Gaillard, from Johns Hopkins School of Medicine, Baltimore, Maryland, begins with the ROSELLA trial of relacorilant plus nab-paclitaxel vs nab-paclitaxel alone in patients with platinum-resistant ovarian cancer. The results showed improved progression-free survival (PFS) and overall survival (OS) in this difficult-to-treat population. Next, she discusses the TRUST trial in advanced ovarian cancer, comparing radical upfront surgical therapy followed by chemotherapy with neoadjuvant chemotherapy followed by surgery, followed by further chemotherapy. Although PFS was improved by upfront surgery, OS was not, leaving the treatment sequence open to question. Dr Gaillard then reports on an updated survival analysis from the OVATION-2 study of intraperitoneal IMNN-001 plus neoadjuvant chemotherapy in newly diagnosed advanced epithelial ovarian cancer. The approach achieved impressive OS, alongside the previously reported PFS benefit. Finally, she reports on a phase 2 study of pembrolizumab and lenvatinib in recurrent or persistent clear cell ovarian carcinoma. The combination showed encouraging response rates and PFS in a population known to be highly resistant to chemotherapy.
